MONICA DHADUK: Open Payments
NPI 1598473092 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$239 in 13 payments from 10 companies in 2025. Trend: 2023 $1,916 · 2024 $1,478 · 2025 $239
Food & beverage: $239
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Averitas Pharma Inc. | 1 | $31 |
| Seqirus USA Inc | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| TOLMAR, INC. | 1 | $14 |
| Amgen Inc. | 1 | $14 |
Products named: MOUNJARO, AIRSUPRA, QUTENZA, Flucelvax, XIFAXAN, SHINGRIX, Kerendia, TRELEGY ELLIPTA.
Industry payments across MD — which companies pay providers there.
